{"links": [{"source": 0, "target": "t2718", "value": "None"}, {"source": 0, "target": "t2710", "value": "None"}, {"source": 0, "target": "t2732", "value": "None"}, {"source": 0, "target": "t2711", "value": "None"}, {"source": 0, "target": "t2716", "value": "None"}, {"source": 0, "target": "t2738", "value": "None"}, {"source": 0, "target": "t2728", "value": "None"}, {"source": "t2718", "target": "t2719", "value": "None"}, {"source": "t2718", "target": "t2724", "value": "None"}, {"source": "t2732", "target": "t2736", "value": "None"}, {"source": "t2711", "target": "t2712", "value": "None"}, {"source": "t2711", "target": "t2713", "value": "None"}, {"source": "t2716", "target": "t2717", "value": "None"}, {"source": "t2738", "target": "t2739", "value": "None"}, {"source": "t2738", "target": "t2741", "value": "None"}, {"source": "t2738", "target": "t2740", "value": "None"}, {"source": "t2728", "target": "t2729", "value": "None"}, {"source": "t2719", "target": "t2720", "value": "None"}, {"source": "t2724", "target": "t2725", "value": "None"}, {"source": "t2724", "target": "t2726", "value": "None"}, {"source": "t2724", "target": "t2727", "value": "None"}, {"source": "t2736", "target": "t2737", "value": "None"}, {"source": "t2712", "target": "t2713", "value": "None"}, {"source": "t2712", "target": "d383", "value": "None"}, {"source": "t2712", "target": "d165", "value": "None"}, {"source": "t2713", "target": "t2714", "value": "None"}, {"source": "t2713", "target": "d227", "value": "None"}, {"source": "t2713", "target": "d383", "value": "None"}, {"source": "t2729", "target": "t2730", "value": "None"}, {"source": "t2720", "target": "t2721", "value": "None"}, {"source": "t2725", "target": "d409", "value": "None"}, {"source": "t2725", "target": "d126", "value": "None"}, {"source": "t2714", "target": "t2715", "value": "None"}, {"source": "t2730", "target": "t2731", "value": "None"}, {"source": "t2721", "target": "t2722", "value": "None"}, {"source": "t2731", "target": "t2735", "value": "None"}, {"source": "t2731", "target": "t2733", "value": "None"}, {"source": "t2722", "target": "t2723", "value": "None"}, {"source": "t2733", "target": "t2734", "value": "None"}, {"source": "t2734", "target": "t2736", "value": "None"}], "nodes": [{"category": "disease", "id": 0, "name": "Constipation", "x": "250", "y": "350", "fixed": "true", "draggable": "true", "value": {"name": "Constipation"}}, {"category": "treatment", "id": "t2718", "name": "person with possible constipation", "draggable": "true", "value": {"name": "person with possible constipation", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with possible constipation", "drug": {}}}, {"category": "treatment", "id": "t2710", "name": "child or young person with idiopathic constipation", "draggable": "true", "value": {"name": "child or young person with idiopathic constipation", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:child or young person with idiopathic constipation", "drug": {}}}, {"category": "treatment", "id": "t2732", "name": "amber flag found (faltering growth or possible maltreatment) or perianal streptococcal infection", "draggable": "true", "value": {"name": "amber flag found (faltering growth or possible maltreatment) or perianal streptococcal infection", "type": "treatment related", "time": "", "intention": "", "description": "title:amber flag found (faltering growth or possible maltreatment) or perianal streptococcal infectionhead:Amber flag found (faltering growth or possible maltreatment) or perianal streptococcal infectionsubhead:Faltering growth (amber flag)If the history-taking or physical examination shows evidence of faltering growth, treat for constipation and test for coeliac disease and hypothyroidism. See what NICE says on coeliac disease and faltering growth.subhead:Possible maltreatment (amber flag)If the history-taking or physical examination shows evidence of possible child maltreatment, treat for constipation and refer to what NICE says on child abuse and neglect.subhead:Perianal streptococcal infectionIf the physical examination shows evidence of perianal streptococcal infection, treat for constipation and also treat the infection.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99", "drug": {}}}, {"category": "treatment", "id": "t2711", "name": "", "draggable": "true", "value": {"name": "", "type": "treatment related", "time": "", "intention": "", "description": "", "drug": {}}}, {"category": "treatment", "id": "t2716", "name": "information, support and follow up", "draggable": "true", "value": {"name": "information, support and follow up", "type": "treatment related", "time": "", "intention": "", "description": "title:information, support and follow-uphead:Information, support and follow-upProvide tailored follow-up to children and young people and their parents or carers according to the child or young person s response to treatment, measured by frequency, amount and consistency of stools (use the Bristol Stool Form Scale to assess this). This could include: telephoning or face-to-face talks giving detailed information about their condition and its management, such as information for the public for constipation in children and young people giving verbal information supported by (but not replaced by) written or website information in several formats about how the bowels work, symptoms that might indicate a serious underlying problem, how to take their medication, what to expect when taking laxatives, how to poo, origins of constipation, criteria to recognise risk situations for relapse (such as worsening of any symptoms, soiling) and the importance of continuing treatment until advised otherwise by the healthcare professional.Offer children and young people with idiopathic constipation and their families a point of contact with specialist healthcare professionals, including school nurses, who can give ongoing support. Liaise with school nurses to provide information and support, and to help them raise awareness of the issues surrounding constipation with pupils and school staff.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.3Reviewing disimpaction therapy4Reviewing maintenance therapy5Written informationSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99", "drug": {}}}, {"category": "treatment", "id": "t2738", "name": "child or young person with unresolved symptoms or intractable constipation", "draggable": "true", "value": {"name": "child or young person with unresolved symptoms or intractable constipation", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:child or young person with unresolved symptoms or intractable constipation", "drug": {}}}, {"category": "treatment", "id": "t2728", "name": "child or young person with possible constipation", "draggable": "true", "value": {"name": "child or young person with possible constipation", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:child or young person with possible constipation", "drug": {}}}, {"category": "treatment", "id": "t2719", "name": "child or young person", "draggable": "true", "value": {"name": "child or young person", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:child or young person", "drug": {}}}, {"category": "treatment", "id": "t2724", "name": "adult", "draggable": "true", "value": {"name": "adult", "type": "treatment related", "time": "", "intention": "", "description": "title:adulthead:AdultNICE has published a clinical knowledge summary on constipation in adults. This practical resource is for primary care professionals (it is not formal NICE guidance).", "drug": {}}}, {"category": "treatment", "id": "t2736", "name": "assess for faecal impaction", "draggable": "true", "value": {"name": "assess for faecal impaction", "type": "treatment related", "time": "", "intention": "", "description": "title:assess for faecal impactionhead:Assess for faecal impactionAssess all children and young people with idiopathic constipation for faecal impaction, including those originally referred for red flags but in whom there were no significant findings (see the key components of history-taking table and the key components of physical examination table). Use a combination of history-taking and physical examination to diagnose faecal impaction \u2013 look for overflow soiling and/or faecal mass palpable abdominally and/or rectally if indicated.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99", "drug": {}}}, {"category": "treatment", "id": "t2712", "name": "disimpaction", "draggable": "true", "value": {"name": "disimpaction", "type": "treatment related", "time": "", "intention": "lactulose\nlactulose is used to treat chronic constipation.\nlactulose is sometimes used to treat or prevent certain conditions of the brain that are caused by liver failure, which can lead to confusion, problems with memory or thinking, behavior changes, tremors, feeling irritable, sleep problems, loss of coordination, and loss of consciousness.\nlactulose may also be used for purposes not listed in this medication guide.", "description": "title:disimpactionhead:DisimpactionOffer the following oral medication regimen: Polyethylene glycol 3350 + electrolytesAt the time these recommendations were written [January 2013], Movicol Paediatric Plain is the only macrogol licensed for children under 12 years that includes electrolytes. It does not have UK marketing authorisation for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years. Informed consent should be obtained and documented. Movicol Paediatric Plain is the only macrogol licensed for children under 12 years that is also unflavoured. using an escalating dose regimen (see laxative recommended doses table) as the first-line treatment. Polyethylene glycol 3350 + electrolytes may be mixed with a cold drink. Add a stimulant laxative if polyethylene glycol 3350 + electrolytes does not lead to disimpaction after 2 weeks. Substitute a stimulant laxative singly or in combination with an osmotic laxative such as lactulose if polyethylene glycol 3350 + electrolytes is not tolerated.Inform families that disimpaction treatment can initially increase symptoms of soiling and abdominal pain.Do not use the following unless all oral medications have failed: rectal medications (and only if the child or young person and their family consent) sodium citrate enemas.Do not use phosphate enemas unless under specialist supervision in hospital/health centre/clinic, and if all oral medications and sodium citrate enemas have failed.Do not perform manual evacuation of the bowel under anaesthesia unless all oral and rectal medications have failed.Review all children undergoing disimpaction within 1 week.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.2First-line treatment with laxatives3Reviewing disimpaction therapySourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99", "drug": {}}}, {"category": "treatment", "id": "t2713", "name": "maintenance therapy", "draggable": "true", "value": {"name": "maintenance therapy", "type": "treatment related", "time": "", "intention": "docusate\notc labeling: when used for self-medication, do not use for longer than 7 days; when abdominal pain, nausea, or vomiting is present; or concomitantly with mineral oil (oral products only)\ndosage forms specific issues:\u2022 benzyl alcohol and derivatives: some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (\u226599 mg/kg/day) have been associated with a potentially fatal toxicity (\u201cgasping syndrome\u201d) in neonates; the \u201cgasping syndrome\u201d consists of metabolic acidosis, respiratory distress, gasping respirations, cns dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (aap 1997; cdc 1982); some data suggests that benzoate displaces bilirubin.\u2022 enema: for rectal use only; lubricate tip prior to insertion. discontinue use and notify health care provider if rash around the anus/rectal irritation occurs or if resistance is encountered with insertion; forcing the tube may result in injury or damage to the rectum.other warnings/precautions:\u2022 self-medication (otc use): when used for self-medication (otc), patients should be instructed to contact healthcare provider prior to use if nausea, stomach  pain, or vomiting are present, or if a sudden change in bowel habits occurs and persists over 14 days. patients should discontinue use and notify healthcare provider if rectal bleeding occurs, if a bowel movement fails to occur after use, or if use is needed >7 days.", "description": "title:maintenance therapyhead:Maintenance therapyStart maintenance therapy if the child or young person is not faecally impacted or as soon as their bowel is disimpacted.Reassess the child or young person frequently during maintenance treatment to ensure they do not become reimpacted and assess issues in maintaining treatment such as taking medicine and toileting. Tailor the frequency of assessment to the individual needs of the child and their families (this could range from daily contact to contact every few weeks). Where possible, reassessment should be provided by the same person/team.Offer the following regimen for ongoing treatment or maintenance therapy:  Polyethylene glycol 3350 + electrolytes as the first-line treatmentAt the time these recommendations were written [January 2013], Movicol Paediatric Plain is the only macrogol licensed for children under 12 years that includes electrolytes. It does not have UK marketing authorisation for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years. Informed consent should be obtained and documented. Movicol Paediatric Plain is the only macrogol licensed for children under 12 years that is also unflavoured.. Adjust the dose of polyethylene glycol 3350 + electrolytes according to symptoms and response. As a guide for children and young people who have had disimpaction the starting maintenance dose might be half the disimpaction dose (see laxatives recommended doses table). Add a stimulant laxative  (see laxatives recommended doses table) if polyethylene glycol 3350 + electrolytes does not work.  Substitute a stimulant laxative if polyethylene glycol 3350 + electrolytes is not tolerated by the child or young person. Add another laxative such as lactulose or docusate (see laxatives recommended doses table) if stools are hard. Continue medication at maintenance dose for several weeks after regular bowel habit is established \u2013 this may take several months. Children who are toilet training should remain on laxatives until toilet training is well established. Do not stop medication abruptly: gradually reduce the dose over a period of months in response to stool consistency and frequency. Some children and young people may require laxative therapy for several years. A minority may require ongoing laxative therapy.Quality standardsThe following quality statements are relevant to this part of the interactive flowchart.2First-line treatment with laxatives4Reviewing maintenance therapySourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99", "drug": {}}}, {"category": "treatment", "id": "t2717", "name": "referral if no response to initial treatment", "draggable": "true", "value": {"name": "referral if no response to initial treatment", "type": "treatment related", "time": "", "intention": "", "description": "title:referral if no response to initial treatmenthead:Referral Refer children and young people with idiopathic constipation that does not respond to initial treatment within 3 months to a practitioner with expertise in the problem.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.6Referral if no response to treatmentSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99", "drug": {}}}, {"category": "treatment", "id": "t2739", "name": "clinical investigations", "draggable": "true", "value": {"name": "clinical investigations", "type": "treatment related", "time": "", "intention": "", "description": "title:clinical investigationshead:Clinical investigationsTest for coeliac disease (see what NICE says on coeliac disease) and hypothyroidism in the ongoing management of intractable constipation if requested by specialist services.Consider using the following investigations only if requested by specialist services in the ongoing management of intractable constipation: plain abdominal radiograph transit studies abdominal ultrasound.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99", "drug": {}}}, {"category": "treatment", "id": "t2741", "name": "antegrade colonic enema procedure", "draggable": "true", "value": {"name": "antegrade colonic enema procedure", "type": "treatment related", "time": "", "intention": "", "description": "title:antegrade colonic enema procedurehead:Antegrade colonic enema procedureRefer children and young people with idiopathic constipation who still have unresolved symptoms on optimum management to a paediatric surgical centre to assess their suitability for an ACE procedure.Ensure that all children and young people who are referred for an ACE procedure have access to support, information and follow-up from paediatric healthcare professionals with experience in this procedure.subhead:Peristeen transanal irrigation system for managing bowel dysfunction The following recommendations are from NICE medical technologies guidance on Peristeen transanal irrigation system for managing bowel dysfunction.The case for adopting Peristeen for transanal irrigation in people with bowel dysfunction is supported by the evidence. Peristeen can reduce the severity of constipation and incontinence, improve quality of life and promote dignity and independence.Peristeen may not be suitable for all people with bowel dysfunction. It may take several weeks before a person is comfortable with using Peristeen, and some people may choose to stop using it. Peristeen is therefore most effective when it is offered with specialist training for users, carers and NHS staff, and structured patient support.Cost modelling for Peristeen is uncertain, but it is likely that Peristeen provides additional clinical benefits without costing more than standard bowel care.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99MTG36", "drug": {}}}, {"category": "treatment", "id": "t2740", "name": "psychological and behavioural interventions", "draggable": "true", "value": {"name": "psychological and behavioural interventions", "type": "treatment related", "time": "", "intention": "", "description": "title:psychological and behavioural interventionshead:Psychological and behavioural interventionsDo not use biofeedback for ongoing treatment.Do not routinely refer children and young people with idiopathic constipation to a psychologist or child and adolescent mental health services unless the child or young person has been identified as likely to benefit from receiving a psychological intervention.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99", "drug": {}}}, {"category": "treatment", "id": "t2729", "name": "establish whether constipation is present", "draggable": "true", "value": {"name": "establish whether constipation is present", "type": "treatment related", "time": "", "intention": "", "description": "title:establish whether constipation is presenthead:Establish whether constipation is presentEstablish during history-taking whether the child or young person has constipation. Two or more findings from the key components of history-taking to diagnose constipation table indicate constipation.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99", "drug": {}}}, {"category": "treatment", "id": "t2720", "name": "history taking and physical examination", "draggable": "true", "value": {"name": "history taking and physical examination", "type": "information and support", "time": "", "intention": "", "description": "title:history-taking and physical examination", "drug": {}}}, {"category": "treatment", "id": "t2725", "name": "chronic idiopathic constipation", "draggable": "true", "value": {"name": "chronic idiopathic constipation", "type": "treatment related", "time": "", "intention": "lubiprostone\nlubiprostone is used to treat chronic constipation, or constipation caused by opioid (narcotic) pain medicine.\nlubiprostone may also be used to treat irritable bowel syndrome in women with constipation as the main symptom.\nlubiprostone may also be used for purposes not listed in this medication guide.", "description": "title:chronic idiopathic constipationhead:Chronic idiopathic constipationsubhead:Possible treatmentsLubiprostone The following recommendation is from NICE technology appraisal guidance on lubiprostone for treating chronic idiopathic constipation. Lubiprostone is recommended as an option for treating chronic idiopathic constipation, that is, for adults in whom treatment with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and for whom invasive treatment for constipation is being considered.If treatment with lubiprostone is not effective after 2 weeks, the person should be re-examined and the benefit of continuing treatment reconsidered.Lubiprostone should only be prescribed by a clinician with experience of treating chronic idiopathic constipation, who has carefully reviewed the person s previous courses of laxative treatments specified above.NICE has written information for the public on lubiprostone.Prucalopride for chronic constipation in womenThe following recommendation is from NICE technology appraisal guidance on prucalopride for the treatment of chronic constipation in women. Prucalopride is recommended as an option for the treatment of chronic constipation only in women for whom treatment with at least two laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and invasive treatment for constipation is being considered.If treatment with prucalopride is not effective after 4 weeks, the woman should be re-examined and the benefit of continuing treatment reconsidered.Prucalopride should only be prescribed by a clinician with experience of treating chronic constipation, who has carefully reviewed the woman s previous courses of laxative treatments specified above.NICE has written information for the public on prucalopride.Peristeen transanal irrigation system for managing bowel dysfunction The following recommendations are from NICE medical technologies guidance on Peristeen transanal irrigation system for managing bowel dysfunction.The case for adopting Peristeen for transanal irrigation in people with bowel dysfunction is supported by the evidence. Peristeen can reduce the severity of constipation and incontinence, improve quality of life and promote dignity and independence.Peristeen may not be suitable for all people with bowel dysfunction. It may take several weeks before a person is comfortable with using Peristeen, and some people may choose to stop using it. Peristeen is therefore most effective when it is offered with specialist training for users, carers and NHS staff, and structured patient support.Cost modelling for Peristeen is uncertain, but it is likely that Peristeen provides additional clinical benefits without costing more than standard bowel care.subhead:Clinical investigationAssessing motility of the gastrointestinal tract using a wireless capsuleNICE has published interventional procedures guidance on assessing motility of the gastrointestinal tract using a wireless capsule with special arrangements for clinical governance, consent and audit or research.SourcesTA318TA211MTG36", "drug": {}}}, {"category": "treatment", "id": "t2726", "name": "opioid induced constipation", "draggable": "true", "value": {"name": "opioid induced constipation", "type": "treatment related", "time": "", "intention": "", "description": "title:opioid-induced constipationhead:Opioid-induced constipationsubhead:NaloxegolThe following recommendation is from NICE technology appraisal guidance on naloxegol for treating opioid-induced constipation. Naloxegol is recommended, within its marketing authorisation, as an option for treating opioid-induced constipation in adults whose constipation has not adequately responded to laxatives.  An inadequate response is defined as opioid-induced constipation symptoms of at least moderate severity in at least 1 of the 4 stool symptom domains (that is, incomplete bowel movement, hard stools, straining or false alarms) while taking at least 1 laxative class for at least 4 days during the prior 2 weeks.NICE has written information for the public on naloxegol. subhead:Methylnaltrexone bromideThe NICE technology appraisal of methylnaltrexone bromide for treating opioid-induced constipation was terminated because no evidence submission was received from Swedish Orphan Biovitrum Ltd. The company has confirmed that it does not intend to make a submission. Therefore NICE was unable to make a recommendation about the use of this technology in the NHS, but will review this decision if the company decides that it wants to make an evidence submission.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. TA345TA468", "drug": {}}}, {"category": "treatment", "id": "t2727", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t2737", "name": "clinical management", "draggable": "true", "value": {"name": "clinical management", "type": "treatment related", "time": "", "intention": "", "description": "title:clinical management", "drug": {}}}, {"category": "treatment", "id": "t2714", "name": "diet and lifestyle", "draggable": "true", "value": {"name": "diet and lifestyle", "type": "treatment related", "time": "", "intention": "", "description": "title:diet and lifestylehead:Diet and lifestyleDo not use dietary interventions alone as first-line treatment.Treat constipation with laxatives and a combination of: Negotiated and non-punitive behavioural interventions suited to the child or young person s stage of development. This could include scheduled toileting and support to establish a regular bowel habit, maintenance and discussion of a bowel diary, information on constipation, and use of encouragement and rewards systems. Dietary modifications to ensure a balanced diet and sufficient fluids are consumed.Advise parents and children or young people (if appropriate) that a balanced diet should include:  Adequate fluid intake (see below). Adequate fibre. Recommend including foods with a high fibre content (such as fruit, vegetables, high-fibre bread, baked beans and wholegrain breakfast cereals) (not applicable to exclusively breastfed infants). Do not recommend unprocessed bran, which can cause bloating and flatulence and reduce the absorption of micronutrients.Give written information about diet and fluid intake to children and young people and their families.Start a cows  milk exclusion diet only on the advice of the relevant specialist services.Advise daily physical activity that is tailored to the child or young person s stage of development and individual ability as part of ongoing maintenance.American dietary recommendationsInstitute of Medicine (2005) Dietary reference intakes for water, potassium, sodium chloride and sulfate. Washington DC: The National Academies Press.Age Total water intake/day (including water in food)Water from drinks/day Infants 0\u20136 months 700 ml assumed to be from breast milk 7\u201312 months 800 ml from milk and complementary foods and beverages 600 ml 1\u20133 years 1300 ml 900 ml 4\u20138 years 1700 ml 1200 ml Boys 9\u201313 years 2400 ml 1800 ml Girls 9\u201313 years 2100 ml 1600 ml Boys 14\u201318 years 3300 ml 2600 ml Girls 14\u201318 years 2300 ml 1800 ml The above recommendations are for adequate intakes and should not be interpreted as a specific requirement. Higher intakes of total water will be needed for those who are physically active or who are exposed to hot environments. It should be noted that obese children and young people may also need higher total intakes of water. SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99", "drug": {}}}, {"category": "treatment", "id": "t2730", "name": "tests that should not be used", "draggable": "true", "value": {"name": "tests that should not be used", "type": "treatment related", "time": "", "intention": "", "description": "title:tests that should not be usedhead:Tests that should not be usedDo not use the following to help diagnose idiopathic constipation: abdominal ultrasound gastrointestinal endoscopy plain abdominal radiograph transit studies.subhead:Tests that should not normally be usedDo not perform rectal biopsy unless any of the following clinical features of Hirschsprung s disease are or have been present: delayed passage of meconium (more than 48 hours after birth in term babies) constipation since first few weeks of life chronic abdominal distension plus vomiting family history of Hirschsprung s disease faltering growth in addition to any of the previous features.Do not use anorectal manometry to exclude Hirschsprung s disease in children or young people with chronic constipation.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99", "drug": {}}}, {"category": "treatment", "id": "t2721", "name": "clinical management", "draggable": "true", "value": {"name": "clinical management", "type": "treatment related", "time": "", "intention": "", "description": "title:clinical management", "drug": {}}}, {"category": "treatment", "id": "t2715", "name": "digital rectal examination", "draggable": "true", "value": {"name": "digital rectal examination", "type": "treatment related", "time": "", "intention": "", "description": "title:digital rectal examinationhead:Digital rectal examinationRefer urgently, to a healthcare professional competent to perform a digital rectal examination and interpret features of anatomical abnormalities or Hirschsprung s disease, children younger than 1 year with idiopathic constipation that does not respond to optimum treatment within 4 weeks.Digital rectal examination should be undertaken only by healthcare professionals competent to interpret features of anatomical abnormalities or Hirschsprung s diseaseEnsure: privacy informed consent is given by the child or young person, or the parent or legal guardian if the child or young person is not able to give it, and is documented a chaperone is present the child or young person s individual preferences about degree of body exposure and gender of the examiner are taken into account all findings are documented.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99", "drug": {}}}, {"category": "treatment", "id": "t2731", "name": "take a history and carry out a physical examination", "draggable": "true", "value": {"name": "take a history and carry out a physical examination", "type": "treatment related", "time": "", "intention": "", "description": "title:take a history and carry out a physical examinationhead:Take a history and carry out a physical examinationIf the child or young person has constipation: Take a history using the key components of history-taking to diagnose idiopathic constipation table to establish a positive diagnosis of idiopathic constipation by excluding underlying causes.  Do a physical examination. Use the key components of physical examination to diagnose idiopathic constipation table to establish a positive diagnosis of idiopathic constipation by excluding underlying causes. If a child or young person has any  red flag  symptoms, do not treat them for constipation. Instead, refer them urgently to a healthcare professional with experience in the specific aspect of child health that is causing concern. Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.1AssessmentSourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99", "drug": {}}}, {"category": "treatment", "id": "t2722", "name": "specialist investigations and interventions", "draggable": "true", "value": {"name": "specialist investigations and interventions", "type": "information and support", "time": "", "intention": "", "description": "title:specialist investigations and interventions", "drug": {}}}, {"category": "treatment", "id": "t2735", "name": "red flag found", "draggable": "true", "value": {"name": "red flag found", "type": "treatment related", "time": "", "intention": "", "description": "title:red flag foundhead:Red flag foundFor information about red flags, see the key components of history-taking to diagnose idiopathic constipation and key components of physical examination to diagnose idiopathic constipation tables.Do not treat for constipation. Refer urgently for tests to a healthcare professional experienced in the specific aspect of child health that is causing concern.subhead:Investigate possible underlying causesDo not perform digital rectal examination in children or young people older than 1 year with a red flag.Refer urgently to a healthcare professional competent to perform a digital rectal examination and interpret features of anatomical abnormalities or Hirschsprung s disease.Digital rectal examination should be undertaken only by healthcare professionals competent to interpret features of anatomical abnormalities or Hirschsprung s disease. Ensure: privacy informed consent is given by the child or young person, or the parent or legal guardian if the child or young person is not able to give it, and is documented a chaperone is present the child or young person s individual preferences about degree of body exposure and gender of the examiner are taken into account all findings are documented.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99", "drug": {}}}, {"category": "treatment", "id": "t2733", "name": "idiopathic constipation established", "draggable": "true", "value": {"name": "idiopathic constipation established", "type": "treatment related", "time": "", "intention": "", "description": "title:idiopathic constipation established", "drug": {}}}, {"category": "treatment", "id": "t2723", "name": "transition from childrens to adults services", "draggable": "true", "value": {"name": "transition from childrens to adults services", "type": "information and support", "time": "", "intention": "", "description": "title:transition from childrens to adults services", "drug": {}}}, {"category": "treatment", "id": "t2734", "name": "inform about diagnosis of idiopathic constipation", "draggable": "true", "value": {"name": "inform about diagnosis of idiopathic constipation", "type": "treatment related", "time": "", "intention": "", "description": "title:inform about diagnosis of idiopathic constipationhead:Inform about diagnosis of idiopathic constipationInform the child or young person and his or her parents or carers of a positive diagnosis of idiopathic constipation and that underlying causes have been excluded by the history and/or physical exam.Reassure them that there is a suitable treatment but it may take several months for the condition to be resolved.NICE has written information for the public on constipation in children and young people.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. CG99", "drug": {}}}, {"category": "drug", "id": "d383", "name": "lactulose", "draggable": "true", "value": {"name": "lactulose", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d165", "name": "citrate", "draggable": "true", "value": {"name": "citrate", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d227", "name": "docusate", "draggable": "true", "value": {"name": "docusate", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d409", "name": "lubiprostone", "draggable": "true", "value": {"name": "lubiprostone", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d126", "name": "capsules", "draggable": "true", "value": {"name": "capsules", "time": "None", "period": "None", "dosage": "None"}}]}